Navigation Links
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
Date:5/15/2008

harmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this rele
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
7. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Inc. (Nasdaq: MYL ) and Pfizer Inc. (NYSE: ... a Pfizer subsidiary, has entered into a settlement agreement with ... abbreviated new drug application (ANDA) for a generic epinephrine auto-injector. ... Teva may launch a generic epinephrine auto-injector covered by its ...
... 2012 Shire plc (LSE: SHP, NASDAQ: ... for the three months to March 31, 2012. ... $1,172 Total revenues million +21% Non GAAP operating income $362 ... GAAP diluted earnings per ADS $1.48 +20% US GAAP diluted ...
Cached Medicine Technology:Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva 2Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 2Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 3Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 4Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 5Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 6Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 7Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 8Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 9Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 10Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 11Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 12Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 13Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 14Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 15Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 16Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 17Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 18Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 19Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 20Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 21Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 22Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 23Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 24Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 25
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/8/2014)... similar longevity and cardiovascular health as other healthy mature ... American Journal of Transplantation . The findings may ... the transplant professionals caring for them. , Over the ... 55 years and older has become more common. Given ... disease, the removal of a kidney could make older ...
(Date:7/8/2014)... from Plymouth, UK, and Sydney, Australia, have today (Wednesday ... ACEmobile - a free-to-use app to support the assessment ... first of its kind; an iPad-based tool that supports ... the whole process, meaning more members of the clinical ... assessment. Designed by clinicians for clinicians, ACEmobile also collects ...
(Date:7/8/2014)... a biomarker that could give expecting mothers and their ... that a pregnant woman may develop preeclampsia, at least ... Preeclampsia is a cardiovascular disorder generally occurring late in ... immediate and potentially lifelong risks to both mother and ... the urine, and is typically diagnosed in the late ...
Breaking Medicine News(10 mins):Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... series feature eight model methods for effective prospect ... has released its first in a series of ... are using prospect research efficiently and with success ... fundraising, includes survey responses from 60 hospitals and ...
... 1 on annual listOAKLAND, Calif., March 5 ... has been recognized by DiversityMBA ... organization was ranked No. 1 in the publication,s fourth ... for Diverse Managers to Work," which will hit newsstands ...
... To Beaver, Star Jerry MathersJACKSON, Miss., March 5 ... will be stopping in Mississippi the week of March ... to help uninsured and financially-struggling Mississippians access information on ... free. With the unemployment rate in Mississippi (7.8 percent) ...
... for low intake of Omega-3 EPA/DHA amongst , childrenHALIFAX, ... the Journal of Nutrition found that most Canadian children ... 78% of the children trialed were not receiving adequate ... , Researchers from the University of Guelph ...
... ANGELES, March 5 With the nation focused on ... recently announced Assembly Bill 562 ( AB ... businesses and consumers that have fallen victim to price ... health care premium costs. It requires insurance companies to ...
... 5 Ascension Insurance, Inc. has announced ... Lauderdale, effective January 16th 2009. The agency specializes in ... (EMI), a member of the Ascension group of companies ... the Ascension group is managed by Ascension Insurance, Inc. ...
Cached Medicine News:Health News:WealthEngine Releases Best Practices Report for Healthcare Fundraising 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 2Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 3Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 4Health News:New Health Care Legislation Stops 'Opportunistic' Insurance Pricing 2Health News:Ascension Insurance, Inc. Acquires Fort Lauderdale-based Dennis Bartlett Agency 2
Our 2.5v Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
... are standard in all Welch Allyn ... students, the 18335-SDS combines the superior ... the superior illumination of the Halogen ... of the Finnoff Transilluminator, and the ...
Our 2.5v Streak Retinoscope Sets feature instruments with bright light, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: